Eur J Cancer . Immune Checkpoint Inhibitors: A Physiology-Driven Approach to the Treatment of Coronavirus Disease 2019

[tetano]

Eur J Cancer


. 2020 Jun 4;135:62-65.
doi: 10.1016/j.ejca.2020.05.026. Online ahead of print.
Immune Checkpoint Inhibitors: A Physiology-Driven Approach to the Treatment of Coronavirus Disease 2019


Serena Di Cosimo ¹ , Andrea Malfettone ² , Jos? M P?rez-Garc?a ³ , Antonio Llombart-Cussac ⁴ , Rosalba Miceli ⁵ , Giuseppe Curigliano ⁶ , Javier Cort?s ⁷



Affiliations

• PMID: 32544799
• DOI: 10.1016/j.ejca.2020.05.026

Abstract

Although confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence.

Keywords: Anti–IL-6R; Anti–PD-1; COVID-19; Cytokine storm; Pembrolizumab; SARS-CoV-2; Tocilizumab.